16
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T28137 |
NC9 TG2 inhibitor
NC 9,NC-9 TG2 inhibitor,NC9 |
||
NC9 is an irreversible inhibitor of transglutaminase 2 (TG2) and also inhibits Factor XIIIA (FXIIIA). | |||
T69933 |
VA4 TG2 inhibitor
|
||
VA4 is a novel irreversible TG2 transamidase site-specific inhibitor. | |||
T26494 |
AA10 TG2 inhibitor
AA 10,AA10,AA-10 |
||
AA10 is an irreversible inhibitor of transglutaminase 2 (TG2). | |||
T29086 |
VA5 TG2 inhibitor
VA5,VA-5,VA 5 |
||
VA5 is an transamidase inhibitor by direct binding at the transamidase site. VA5 also inhibits GTP-binding activities. It interaction at the transamidase site locks the protein in the extended/open conformation to disorganize/inactivate the GTP binding/GT | |||
T70413 | TG2-IN-3h | ||
TG2-IN-3h is a highly selective, potent, cell-permeable fluorescent irreversible tissue transglutaminase (tg2) inhibitor | |||
T69878 |
AA9 TG2 inhibitor
|
||
AA9 is a novel transglutaminase (TG2) inhibitor. | |||
T79315 |
PROTAC TG2 degrader-2
|
PROTACs | PROTAC |
PROTACTG2 degrader-2(compound 7)是一种针对Transglutaminase 2(TG2)的选择性竞争性降解剂,其Kd值大于100 μM。该化合物能有效抑制卵巢癌细胞的迁移,并降低其TG2表达水平,因此可作为卵巢癌研究的工具。 | |||
T79505 |
PROTAC TG2 degrader-1
|
PROTACs | PROTAC |
PROTACTG2 degrader-1(化合物 11)是一种靶向组织转谷氨酰胺酶 (TG2) 的VHL基PROTAC,具有68.9 μM的KD值。该化合物通过蛋白酶体途径降低卵巢癌细胞中TG2的水平。 | |||
T83855 |
TG2-179-1
|
||
TG2-179-1是BRCA1相关蛋白1(BAP1)的抑制剂。它在25 µM至1.5 mM的浓度范围内,通过无细胞测定法抑制BAP1的去泛素化活性。TG2-179-1对八种结肠癌细胞系表现出细胞毒性(IC50s = 4.48-7.52 µM)。在体内,TG2-179-1(10和30 mg/kg)能够减少HCT116结肠癌小鼠异种移植模型中的肿瘤体积。 | |||
T70412 | PNU-145156E free base | ||
PNU-145156E free base is an angiogenesis inhibitor. | |||
T17289 |
ZED-1227
ZED-101,TAK-227 |
Others; Glutaminase | Others; Proteases/Proteasome |
ZED-1227 (TAK-227) 是一种具有口服活性、选择性和高效性的转谷氨酰胺酶 2 (TG2) 抑制剂,具有抗癌活性,能阻塞炎症诱导的 TG2 表达和激活,可用于治疗乳糜泻。 | |||
T67865 |
BJJF078
|
Glutaminase | Proteases/Proteasome |
BJJF078 是一种氨基哌啶衍生物,是一种有效的重组人和小鼠谷氨酰胺转氨酶 (TG2) 活性的抑制剂,对人和小鼠谷氨酰胺转氨酶的IC50 值分别为 41 和 54 nM。BJJF078 对 TG1 酶有抑制作用,其IC50 为 0.16 μM。 BJJF078 可用于研究多发性硬化症 (MS) 。 | |||
T13783 |
MT-4
|
Others | Others |
MT-4 可阻断肿瘤细胞和肿瘤niche 表面的TG2/FN 复合体。 MT-4抑制卵巢癌(OC)细胞与腹膜的黏附。 | |||
T76951 | Zampilimab | ||
Zampilimab (UCB-7858),一种转谷氨酰胺酶 2 (TG2) 单克隆抗体,具有肾移植潜在应用。 | |||
T26265 |
TG53
TG-53,TG 53 |
||
TG53 is a tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction inhibitor. | |||
T71477 |
CP4d inhibitor
|
||
CP4d is a novel reversible tg2 transamidase site-specific inhibitor |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01355 |
Transglutaminase 2/TGM2 Protein, Human, Recombinant (His)
G-α-h,HEL-S-45,TGC,transglutaminase 2,... |
Human | Baculovirus Insect Cells |
Protein-glutamine gamma-glutamyltransferase 2, also known as Tissue transglutaminase, Transglutaminase C, Transglutaminase-2, and TGM2, is a member of the transglutaminase superfamily. TGM2 plays a role in cell growth and survival through the anti-apoptosis signaling pathway. It is a calcium-dependent acyltransferase that also undergoes a GTP-binding/GTPase cycle even though it lacks any obvious sequence similarity with canonical GTP-binding (G) proteins. TGM2 is a multi-functional protein which... |